Efsevia Vakiani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Efsevia Vakiani has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Nikolaus Schultz
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
199 shared publications - Michael F. Berger
Memorial Sloan Kettering Cancer Center
190 shared publications - Anna M. Varghese
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
126 shared publications - Aijazuddin Syed
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
124 shared publications - Anoop Balakrishnan Rema
Memorial Sloan Kettering Cancer Center
124 shared publications - Gurnit Atwal
Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
124 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF11
Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF11
Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501069
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
PURPOSE: We sought to characterize the genomic landscape of gastroesophageal adenocarcinoma (GEA) using next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), compare the genomic profile to tissue NGS, and determine the association of circulating tumor DNA (ctDNA) detection with clinical outcomes. METHODS: In this prospective biospecimen-collection study (2017-2022), cfDNA was analyzed using a clinically validated 129-gene tumor-informed NGS assay Memorial Sloan Kettering-Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS); tissue-NGS was performed using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In total, 169 patients with GEA underwent baseline molecular profiling of cfDNA; 93 had localized disease, 55 had untreated metastatic disease, and 21 had progressive metastatic disease. The frequency of the most common alterations was similar between platforms, although copy-number alterations were detected less frequently in plasma than in tissue (10% v 40%; P < .001). Matched-tumor NGS was conducted in 154 patients (91%). Baseline ctDNA detection and on-treatment clearance were associated with improved overall survival and recurrence-free survival in patients with localized disease and progression-free survival in patients with metastatic disease. Baseline ctDNA detection was a stronger predictor of overall survival than American Joint Committee on Cancer (AJCC) clinical stage and positively predicted lymph node metastasis in 87% of cases. Trends in variant allele fractions correlated with pathologic responses to neoadjuvant therapy more closely than fluorodeoxyglucose-positron emission tomography standard uptake values. Persistence or resurgence of ctDNA was associated with worse survival and forecasted recurrent disease a median of 7 months sooner than imaging. CONCLUSION: cfDNA analysis using MSK-ACCESS in patients with GEA is a valuable adjunctive clinical tool that enhances molecular profiling, prognostication, treatment response assessment, and detection of recurrent disease in conjunction with tissue NGS, imaging, and AJCC clinical staging criteria.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501069
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
PURPOSE: We sought to characterize the genomic landscape of gastroesophageal adenocarcinoma (GEA) using next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), compare the genomic profile to tissue NGS, and determine the association of circulating tumor DNA (ctDNA) detection with clinical outcomes. METHODS: In this prospective biospecimen-collection study (2017-2022), cfDNA was analyzed using a clinically validated 129-gene tumor-informed NGS assay Memorial Sloan Kettering-Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS); tissue-NGS was performed using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In total, 169 patients with GEA underwent baseline molecular profiling of cfDNA; 93 had localized disease, 55 had untreated metastatic disease, and 21 had progressive metastatic disease. The frequency of the most common alterations was similar between platforms, although copy-number alterations were detected less frequently in plasma than in tissue (10% v 40%; P < .001). Matched-tumor NGS was conducted in 154 patients (91%). Baseline ctDNA detection and on-treatment clearance were associated with improved overall survival and recurrence-free survival in patients with localized disease and progression-free survival in patients with metastatic disease. Baseline ctDNA detection was a stronger predictor of overall survival than American Joint Committee on Cancer (AJCC) clinical stage and positively predicted lymph node metastasis in 87% of cases. Trends in variant allele fractions correlated with pathologic responses to neoadjuvant therapy more closely than fluorodeoxyglucose-positron emission tomography standard uptake values. Persistence or resurgence of ctDNA was associated with worse survival and forecasted recurrent disease a median of 7 months sooner than imaging. CONCLUSION: cfDNA analysis using MSK-ACCESS in patients with GEA is a valuable adjunctive clinical tool that enhances molecular profiling, prognostication, treatment response assessment, and detection of recurrent disease in conjunction with tissue NGS, imaging, and AJCC clinical staging criteria.